INTEGRATED BIOPHARMA INC INBP revenue by segment, product and geography
In its fiscal year ending 2025-06-30, INTEGRATED BIOPHARMA INC reported revenue across 2 business segments; the largest, Contract Manufacturing, was $51.7M, 95.1% of the filed sum (+6.4% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Contract Manufacturing$51.7M95.1%+6.4% yoy
- Other Nutraceutical Business$2.67M4.9%+52.7% yoy
Members sum to the consolidated $54.4M for this period.
- United States$43.6M80.3%+3.0% yoy
- Outside the United States$10.7M19.7%+34.5% yoy
Members sum to the consolidated $54.4M for this period.
- Contract Manufacturing$9.82M97.2%no prior
- Other Nutraceutical Business$284K2.8%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.